keyword
MENU ▼
Read by QxMD icon Read
search

Progesterone receptor breast cancer

keyword
https://www.readbyqxmd.com/read/28811185/the-effect-of-receptor-status-on-mastectomy-and-contralateral-prophylactic-mastectomy-rates-in-early-stage-invasive-breast-carcinoma
#1
Sunil W Dutta, Daniel M Trifiletti, Surbhi Grover, Kara D Romano, Einsley-Marie Janowski, Shayna L Showalter
BACKGROUND: There is an established relationship between hormone receptor (HR; estrogen and/or progesterone receptors) status, HER2 status, and locoregional recurrence. The purpose of this study was to analyze how HR and HER2 receptor status have influenced the surgical management trends among patients with early stage breast cancer. PATIENTS AND METHODS: The National Cancer Database was queried for patients with cT1 to cT3, cN0, and cM0 breast carcinoma from 2004 to 2012...
June 29, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28810691/improvement-of-implantation-potential-in-mouse-blastocysts-derived-from-ivf-by-combined-treatment-with-prolactin-epidermal-growth-factor-and-4-hydroxyestradiol
#2
Miki Takeuchi, Misato Seki, Etsuko Furukawa, Akihito Takahashi, Kyosuke Saito, Mitsuru Kobayashi, Kenji Ezoe, Emiko Fukui, Midori Yoshizawa, Hiromichi Matsumoto
STUDY QUESTION: Can supplementation of medium with prolactin (PRL), epidermal growth factor (EGF) and 4-hydroxyestradiol (4-OH-E2) prior to embryo transfer improve implantation potential in mouse blastocysts derived from IVF? SUMMARY ANSWER: Combined treatment with PRL, EGF and 4-OH-E2 improves mouse blastocyst implantation rates, while alone, each factor is ineffective. WHAT IS KNOWN ALREADY: Blastocyst dormancy during delayed implantation caused by ovariectomy is maintained by continued progesterone treatment in mice, and estrogen injection rapidly activates blastocysts to implantation-induced status in vivo...
August 1, 2017: Molecular Human Reproduction
https://www.readbyqxmd.com/read/28808873/elevated-hu-antigen-receptor-hur-expression-is-associated-with-tumor-aggressiveness-and-poor-prognosis-but-not-with-cox-2-expression-in-invasive-breast-carcinoma-patients
#3
Constantinos Giaginis, Anastasia Sampani, Iolly Kotta-Loizou, Ioanna Giannopoulou, Eugene Danas, Ekaterini Politi, Gerasimos Tsourouflis, Gregorios Kouraklis, Efstratios Patsouris, Antonios Keramopoulos, Lydia Nakopoulou, Stamatios Theocharis
Hu-antigen R (HuR), a RNA-binding protein, is considered to play a crucial role in tumor development and progression by stabilizing or regulating a group of cellular mRNAs of cancer-related genes, such as cyclooxygenase-2 (COX-2). The present study aimed to evaluate the clinical significance of HuR and COX-2 expression in invasive breast carcinoma. HuR and COX-2 protein expression was assessed immunohistochemically on paraffin-embedded breast cancer tissue sections obtained from 121 patients and was statistically analyzed with clinicopathological parameters, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), as well as with tumor cells' proliferative capacity and overall and disease-free patients' survival...
August 14, 2017: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/28799536/estrogen-receptor-esr1-mutation-in-bone-metastases-from-breast-cancer
#4
Stephan Bartels, Matthias Christgen, Angelina Luft, Sascha Persing, Kai Jödecke, Ulrich Lehmann, Hans Kreipe
Activating mutations of estrogen receptor α gene (ESR1) in breast cancer can cause endocrine resistance of metastatic tumor cells. The skeleton belongs to the metastatic sides frequently affected by breast cancer. The prevalence of ESR1 mutation in bone metastasis and the corresponding phenotype are not known. In this study bone metastases from breast cancer (n=231) were analyzed for ESR1 mutation. In 27 patients (12%) (median age 73 years, range: 55-82 years) activating mutations of ESR1 were detected. The most frequent mutation was p...
August 11, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28799059/her2-intratumoral-heterogeneity-is-independently-associated-with-incomplete-response-to-anti-her2-neoadjuvant-chemotherapy-in-her2-positive-breast-carcinoma
#5
Yanjun Hou, Hiroaki Nitta, Lai Wei, Peter M Banks, Bryce Portier, Anil V Parwani, Zaibo Li
PURPOSE: Anti-HER2 neoadjuvant chemotherapy has been widely used in HER2-positive breast cancer patients; however, pathologic complete response (pCR) is achieved in only 40-50% of patients. The aim of this study was to investigate the association of HER2 intratumoral heterogeneity (ITH) with response to anti-HER2 neoadjuvant chemotherapy. METHODS: Assessment of HER2 ITH was performed on whole tissue sections of pre-treatment samples from a cohort of 64 invasive breast carcinoma cases originally considered positive for HER2 and treated with anti-HER2 neoadjuvant chemotherapy...
August 10, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28791816/il-6-il-8-and-tnf-%C3%AE-levels-correlate-with-disease-stage-in-breast-cancer-patients
#6
Yunfeng Ma, Yi Ren, Zhi-Jun Dai, Cai-Jun Wu, Yan-Hong Ji, Jiru Xu
BACKGROUND: Breast cancer is the most common cancer in Chinese women. Inflammation contributes to tumor progression and can be induced by excessive production of pro-inflammatory cytokines such as interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α). However, how their levels relate to the expression of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor 2 (HER2) by the tumor has not been investigated. OBJECTIVES: The aim of the study is to more fully understand the significance of serum IL-6, IL-8 and TNF-α in breast cancers with different ER, PR and HER2 status...
May 2017: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
https://www.readbyqxmd.com/read/28791647/analysis-of-epithelial-mesenchymal-transition-induced-by-overexpression-of-twist
#7
Jing-Wen Bai, Yong-Qu Zhang, Yao-Chen Li, Guo-Jun Zhang
Breast cancer, the most common malignancy among women worldwide, is a heterogeneous disease, and it therefore has remarkably different biological characteristics and clinical behavior. Breast cancer has been divided into several different molecular subtypes based on the status of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 (HER2, also named as ErbB2) status. Her2 is a member of EGFR family of transmembrane tyrosine kinase-type receptors, and is involved in the activation of its downstream signaling cascades, which could promote cell proliferation, metastasis, and angiogenesis in tumors...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/28778029/papillotubular-carcinoma-with-an-invasive-micropapillary-carcinoma-component-of-the-breast-characterized-by-a-rapid-increase-in-size-due-to-intra-tumoral-hemorrhage-a-case-report
#8
Motonobu Watanabe, Ryota Matsuoka, Yukako Ichimura, Toshiro Takagaki, Yasushi Iitsuka
INTRODUCTION: Rapidly enlarging mammary tumors, including invasive breast tumors, are clinically rare. Invasive micropapillary carcinoma (IMPC) of the breast is known to have aggressive behavior and poor clinical course compared to invasive ductal carcinoma. CASE PRESENTATION: An 87-year-old woman presented with a rapidly enlarging tumor of the right breast over the course of 3 weeks. Ultrasonography and computed tomography of the chest revealed a giant tumor located on the right chest wall, with heterogeneous parenchymal components and several cystic lesions...
July 25, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28770448/relationship-between-mammographic-calcifications-and-the-clinicopathologic-characteristics-of-breast-cancer-in-western-china-a-retrospective-multi-center-study-of-7317-female-patients
#9
Ke Zheng, Jin-Xiang Tan, Fan Li, Yu-Xian Wei, Xue-Dong Yin, Xin-Liang Su, Hong-Yuan Li, Qi-Lun Liu, Bin-Lin Ma, Jiang-Hua Ou, Hui Li, Sui-Sheng Yang, Ai-Mei Jiang, Qing Ni, Jian-Lun Liu, Jin-Ping Liu, Hong Zheng, Zhang-Jun Song, Ling Wang, Jian-Jun He, Tian-Ning Zou, Jun Jiang, Guo-Sheng Ren
BACKGROUND AND PURPOSE: Limited information is available regarding the correlations between mammographic calcifications and the epidemiological features of patients with breast cancer living different lifestyles in Western China. Thus, this study aimed to investigate the relationship between mammographic calcifications and the epidemiological characteristics of female patients with breast cancer in Western China. METHODS: This was a hospital-based, retrospective, multi-center epidemiological study of patients with breast cancer...
August 2, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28767397/clinicopathological-characteristics-and-survival-outcomes-of-invasive-lobular-carcinoma-in-different-races
#10
Li-Yuan Yang, Li-Peng Yang, Biao Zhu
To investigate the clinicopathological characteristics and to determine whether there is a differential effect of race and examine survival outcomes according to race, 18,295 breast invasive lobular carcinoma (ILC) patients were identified in the Surveillance, Epidemiology, and End Result (SEER) database, which includes White patients (n=15,936), Black patients (n=1,451) and patients of other races (including American Indians/Alaskan Natives and Asian/Pacific Islanders) (n=908). The Black ILC patients presented a higher rate of advanced histological grades and American Joint Committee on Cancer (AJCC) stages, a higher rate of lymph node (LN) involvement and a lower rate of progesterone receptors (PR)-positivity than the White patients and other races...
July 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28766688/stathmin1-expression-is-associated-with-aggressive-phenotypes-and-cancer-stem-cell-marker-expression-in-breast-cancer-patients
#11
Sayaka Obayashi, Jun Horiguchi, Toru Higuchi, Ayaka Katayama, Tadashi Handa, Bolag Altan, Tuya Bai, Pinjie Bao, Halin Bao, Takehiko Yokobori, Masahiko Nishiyama, Tetsunari Oyama, Hiroyuki Kuwano
Stathmin1 (STMN1) regulates progression in various cancers. The present study aimed to determine the relationship between STMN1 expression and several cancer-related markers in breast cancer. Using immunohistochemistry, we evaluated STMN1, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67, epidermal growth factor receptor (EGFR), CK5/6, CD44, CD24, aldehyde dehydrogenase 1, E-cadherin, epithelial cell adhesion molecule, and vimentin in 237 breast cancer patients and the clinical significance of STMN1...
September 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/28766230/clinical-relevance-of-microrna-expressions-in-breast-cancer-validated-using-the-cancer-genome-atlas-tcga
#12
Sara Y Kim, Tsutomu Kawaguchi, Li Yan, Jessica Young, Qianya Qi, Kazuaki Takabe
BACKGROUND: MicroRNAs (miRNAs) play a critical role in the carcinogenesis and progression of breast cancer. MiRNA-205 has tumor suppressive properties, whereas miRNA-18a has both oncogenic and tumor suppressive roles. MiRNA-744's role in breast cancer is unknown but is tumor-suppressive in vitro. We hypothesize that high expression of all three miRNAs is associated with a better survival based on their known functions in breast cancer. METHODS: All data was obtained from the Cancer Genome Atlas (TCGA)...
August 1, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28766214/factors-influencing-use-of-hormone-therapy-for-ductal-carcinoma-in-situ-a-national-cancer-database-study
#13
Toan T Nguyen, Tanya L Hoskin, Courtney N Day, Elizabeth B Habermann, Matthew P Goetz, Judy C Boughey
BACKGROUND: Adjuvant hormonal therapy (HT) reduces breast cancer recurrence risk in estrogen receptor-positive (ER+) ductal carcinoma in situ (DCIS). We assessed national practice patterns and influence of surgery and pathology on HT use in DCIS. METHODS: Data on DCIS patients diagnosed from 2004 to 2014 were extracted from the National Cancer Database, and patients were classified according to ER status and whether HT was received. Factors associated with HT use were assessed using Chi square tests for univariate analysis and logistic regression for multivariate analysis...
August 1, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28765906/hpk1-positive-expression-associated-with-longer-overall-survival-in-patients-with-estrogen-receptor-positive-invasive-ductal-carcinoma%C3%A2-not-otherwise-specified
#14
Jiaojiao Wang, Lijie Song, Sen Yang, Weijie Zhang, Pengwei Lu, Shenglei Li, Huixiang Li, Liuxing Wang
Hematopoietic progenitor kinase 1 (HPK1) belongs to the mitogen activated protein kinase kinase kinase kinase (MAP4K) family of serine/threonine kinases, which have been associated with the incidence and progression of a variety of gastrointestinal malignant tumors in humans. However, the potential association between HPK1 expression and breast cancer, particularly invasive ductal carcinoma‑not otherwise specified (IDC‑NOS) development, has not yet been examined. To address this gap, the present study aimed to evaluate HPK1 expression in IDC‑NOS samples and to determine a relationship with clinical prognostic indicators, such as the expression levels of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), as well as overall survival of the patients with IDC‑NOS...
August 2, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/28762114/the-optimal-treatment-plan-to-avoid-axillary-lymph-node-dissection-in-early-stage-breast-cancer-patients-differs-by-surgical-strategy-and-tumor-subtype
#15
Melissa Pilewskie, Emily C Zabor, Anita Mamtani, Andrea V Barrio, Michelle Stempel, Monica Morrow
BACKGROUND: Strategies to reduce the likelihood of axillary lymph node dissection (ALND) include application of Z0011 or use of neoadjuvant chemotherapy (NAC). Indications for ALND differ by treatment plan, and nodal pathologic complete response rates after NAC vary by tumor subtype. This study compared ALND rates for cT1-2N0 tumors treated with upfront surgery versus those treated with NAC. METHODS: The ALND rates for cT1-2N0 breast cancer patients were compared by tumor subtype among women undergoing upfront surgery to NAC...
July 31, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28756019/survival-outcome-of-weak-estrogen-progesterone-receptor-expression-in-her2-negative-breast-cancer-is-similar-to-triple-negative-breast-cancer
#16
G-S Liao, M-S Dai, H-M Hsu, C-H Chu, Z-J Hong, C-Y Fu, Y-C Chou, T-C Huang, J-C Yu
BACKGROUND: Recent publications have suggested that human epidermal growth factor receptor 2 (HER2)-negative breast cancers with "weak" estrogen receptor (ER)/progesterone receptor (PR) expression levels by immunohistochemical (IHC) analysis were considered as the triple-negative (TN) subtype. This study aimed to evaluate the overall survival (OS), disease-free survival rates (DFS), and disease-specific survival (DSS) based on ER and PR expression levels into one of three groups, ER and PR <1%, ER and PR 1%-20%, and ER or PR >20% by hormone therapy...
July 19, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28754862/human-her2-overexpressing-mouse-breast-cancer-cell-lines-derived-from-mmtv-f-huher2-mice-characterization-and-use-in-a-model-of-metastatic-breast-cancer
#17
Sunju Park, Jessie R Nedrow, Anders Josefsson, George Sgouros
Preclinical evaluation of therapeutic agents against metastatic breast cancer require cell lines and animal models that recapitulate clinical metastatic breast cancer as much as possible. We have previously used cell lines derived from the neu-N transgenic model to investigate anti-neu targeting of metastatic breast cancer using an alpha-emitter labeled antibody reactive with the rat variant of HER2/neu expressed by the neu-N model. To investigate alpha-particle emitter targeting of metastatic breast cancer using clinically relevant, commercially available anti-HER2/neu antibodies, we have developed cell lines derived from primary tumors and lung metastases from HuHER2 transgenic mice...
July 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/28752191/breast-cancer-family-history-leads-to-early-breast-cancer-detection-and-optimal-management
#18
Anne-Sophie Jannot, Massimo Usel, Christine Bouchardy, Hyma Schubert, Elisabetta Rapiti
PURPOSE: We investigated whether the relationship between family history (FH) of breast cancer and survival of women with breast cancer is related to the quality of care received, once adjusted for other prognostic variables using data from the Geneva population-based cancer registry and quality of care indicators defined by the European Society of breast cancer specialists (EUSOMA). METHODS: We included non-metastatic malignant breast tumor patients who had their surgery between 2001 and 2010...
July 27, 2017: Cancer Causes & Control: CCC
https://www.readbyqxmd.com/read/28751463/dual-src-kinase-pretubulin-inhibitor-kx-01-sensitizes-er%C3%AE-negative-breast-cancers-to-tamoxifen-through-er%C3%AE-re-expression
#19
Muralidharan Anbalagan, Mei Sheng, Brian Fleischer, Yifang Zhang, Yuanjun Gao, Van T Hoang, Margarite D Matossian, Hope E Burks, Matthew E Burow, Bridgette M Collins-Burow, David Hangauer, Brian G Rowan
Unlike breast cancer that is positive for estrogen receptor-α (ERα), there are no targeted therapies for triple negative breast cancer (TNBC). ERα is silenced in TNBC through epigenetic changes including DNA methylation and histone acetylation. Restoring ERα expression in TNBC may sensitize patients to endocrine therapy. Expression of c-Src and ERα are inversely correlated in breast cancer suggesting that c-Src inhibition may lead to re-expression of ERα in TNBC. KX-01 is a peptide substrate-targeted Src/pretubulin inhibitor in clinical trials for solid tumors...
July 27, 2017: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/28750640/impact-of-somatic-pi3k-pathway-and-erbb-family-mutations-on-pathological-complete-response-pcr-in-her2-positive-breast-cancer-patients-who-received-neoadjuvant-her2-targeted-therapies
#20
Sinead Toomey, Alexander J Eustace, Joanna Fay, Katherine M Sheehan, Aoife Carr, Malgorzata Milewska, Stephen F Madden, Ausra Teiserskiene, Elaine W Kay, Norma O'Donovan, William Gallagher, Liam Grogan, Oscar Breathnach, Janice Walshe, Catherine Kelly, Brian Moulton, M John Kennedy, Guiseppe Gullo, Arnold D Hill, Colm Power, Deirdre Duke, Niamh Hambly, John Crown, Bryan T Hennessy
BACKGROUND: The Cancer Genome Atlas analysis revealed that somatic EGFR, receptor tyrosine-protein kinase erbB-2 (ERBB2), Erb-B2 receptor tyrosine kinase 3 (ERBB3) and Erb-B2 receptor tyrosine kinase 4 (ERBB4) gene mutations (ERBB family mutations) occur alone or co-occur with somatic mutations in the gene encoding the phosphatidylinositol 3-kinase (PI3K) catalytic subunit (PIK3CA) in 19% of human epidermal growth factor receptor 2 (HER2)-positive breast cancers. Because ERBB family mutations can activate the PI3K/AKT pathway and likely have similar canonical signalling effects to PI3K pathway mutations, we investigated their combined impact on response to neoadjuvant HER2-targeted therapies...
July 27, 2017: Breast Cancer Research: BCR
keyword
keyword
9275
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"